Boehringer Ingelheim GmbH Release: New Study To Investigate Dabigatran Etexilate For Prevention Of Recurrent Stroke In High-Risk Patients
5/7/2014 8:25:42 AM
INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S., the UK & Canada only.
Details of a new 6,000 patient study of dabigatran etexilate were announced today at the European Stroke Conference, Nice, France. The RE-SPECT ESUS™ study will investigate the blood thinner dabigatran etexilate for the prevention of recurrent stroke in patients who have already suffered an embolic stroke of undetermined source (ESUS).3 Such a stroke occurs when a blood clot (embolus) forms somewhere in the body and travels through the bloodstream to the brain.4 As a company dedicated to preventing and treating stroke, Boehringer Ingelheim will investigate dabigatran etexilate in this area of significant medical need, hoping that even more patients at risk of stroke can benefit from the treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by